We observed at least a twofold difference in individuals with NTRK3 hyper-methylated promoters between lung cancer (15%) and the other 4 cancers (CRC; 36%, stomach; 34%, Oesophagus; 33% and Pancreas 30%) (Fig. 1E). This evidence concerns the gene NTRK3 and cancer.